SENSICARDIAC vs VX1

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

SENSICARDIAC

by Diacoustic Medical Devices (Pty) Ltd.

VX1

by Volta Medical

AI Verdict

SENSICARDIAC is an AI-powered diagnostic tool focused on detecting and classifying heart murmurs using electronic stethoscopes, primarily for screening and aiding physicians in early diagnosis. In contrast, VX1 is an AI-guided software designed to assist cardiac electrophysiologists in real-time during atrial fibrillation and atrial tachycardia ablation procedures by identifying dispersed electrograms. While both are cardiology AI solutions, SENSICARDIAC targets diagnostic workflows, whereas VX1 is for interventional guidance.

Choose SENSICARDIAC if…

Choose SENSICARDIAC if you are a physician in general practice, internal medicine, or pediatrics seeking an AI-powered solution for initial heart murmur screening and remote cardiac monitoring. This tool is ideal for quickly classifying murmurs as pathological or physiological using electronic stethoscopes, helping to streamline diagnoses and reduce unnecessary specialist referrals.

View SENSICARDIAC →

Choose VX1 if…

Choose VX1 if you are a cardiac electrophysiologist performing atrial fibrillation or atrial tachycardia ablation procedures and require real-time AI assistance. This software is specifically designed to identify dispersed electrograms during these complex interventions, aiming to enhance procedural precision and standardize outcomes within the electrophysiology lab.

View VX1 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	SENSICARDIAC	VX1
Pricing	Unknown	Contact for pricing
Deployment	SensiCardiac is a software package running on a Windows PC that interfaces with compatible electronic stethoscopes. SensiCardiac Mobi runs on a mobile device (iPhone 4S or later) and interfaces with a hosted Linux server environment. The related Telesensi platform operates entirely in the browser.	Software integrated with existing electrophysiology (EP) lab mapping and recording systems.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

SENSICARDIAC

SENSICARDIAC (Tool A) offers a guided auscultation process and real-time analysis with a user-friendly graphical interface, which user testing rated highly (over 4 out of 5). Its integration with electronic stethoscopes makes it accessible for a broader range of physicians in various settings. While VX1 (Tool B) has a simple interface for its specialized function, SENSICARDIAC's broader applicability and proven user satisfaction suggest superior general usability.

Clinical Value

VX1

Both tools are FDA-cleared and offer significant clinical value in their respective domains. However, VX1 (Tool B) has published peer-reviewed clinical study results (Ev-AIFib) demonstrating its ability to standardize outcomes and achieve high rates of freedom from AF and acute AF termination during complex ablation procedures. An ongoing randomized controlled trial (TAILORED-AF) further aims to establish it as a new standard of care. While SENSICARDIAC aids in diagnosis and reduces referrals, specific clinical outcome data from studies were not as prominently found in the search results as for VX1.

Pricing & Value

Tie

Both SENSICARDIAC (Tool A) and VX1 (Tool B) explicitly state 'contact for pricing' and do not provide publicly available pricing details. Without transparent information on costs or detailed cost-benefit analyses, it is impossible to definitively determine which tool offers better overall value.

Enterprise Readiness

SENSICARDIAC

SENSICARDIAC (Tool A) explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA) in its specifications. Its cloud-based nature, desktop deployment, and options for white-labeling and centralized user management with integrated billing indicate a strong readiness for scalable deployment and integration within various healthcare systems and telehealth platforms. While VX1 (Tool B) operates in a highly regulated environment and likely adheres to similar standards, these are not explicitly stated in the initial facts.

Innovation

VX1

VX1 (Tool B) demonstrates a higher degree of innovation by being the 'first FDA cleared AI-based tool in interventional cardiac electrophysiology'. Its real-time AI guidance during complex ablation procedures, analyzing 3D anatomical and electrical maps to standardize outcomes, represents a more advanced and specialized application of AI in a high-stakes clinical environment compared to SENSICARDIAC's murmur detection.

Support & Docs

Tie

Both SENSICARDIAC (Tool A) and VX1 (Tool B) provide user manuals and documentation, as indicated by available online resources. Neither product's information explicitly details the breadth of their support services (e.g., 24/7 support, comprehensive training programs, dedicated account managers), making a definitive distinction between the two on this dimension difficult.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	SENSICARDIAC	VX1
Name	SENSICARDIAC	VX1
Company	DIACOUSTIC MEDICAL (PTY)	Volta Medical
Primary Function	AI-powered, cloud-based heart murmur detection service that integrates with electronic stethoscopes to classify murmurs as pathological or physiological, aiding physicians in diagnosis and reducing unnecessary referrals.	FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.
Target Specialties	Cardiology, Internal Medicine, Pediatrics	Cardiology
Key AI Application	AI-powered heart murmur detection and classification (pathological/physiological)	AI-guided real-time identification of dispersed electrograms (EGMs) during ablation procedures
Integration/Compatibility	Integration with electronic stethoscopes (e.g., 3M Littmannu00ae 3200)	Compatible with most EP recording, 3D navigation systems, and mapping catheters

Videos

Demos, reviews, and walkthroughs featuring SENSICARDIAC and VX1.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do SENSICARDIAC and VX1 integrate into distinct clinical workflows, and for what specific patient populations are they best suited?

SENSICARDIAC is designed for general cardiology, internal medicine, and pediatrics, aiding in the screening and diagnosis of heart murmurs in outpatient settings to reduce unnecessary referrals. VX1, conversely, is tailored for cardiac electrophysiologists, providing real-time AI guidance during complex atrial fibrillation and atrial tachycardia ablation procedures in an EP lab environment.

What is the extent of EHR integration for each tool, and how does it impact data flow and documentation within a physician's existing system?

SENSICARDIAC generates detailed cardiac reports as downloadable PDFs, which would likely require manual upload or basic integration into an EHR. VX1 is described as software integrated with existing electrophysiology lab mapping and recording systems, suggesting a more direct and real-time data exchange within the specialized EP workflow.

What specific metrics of accuracy or sensitivity are available for each tool, particularly concerning their primary diagnostic or procedural assistance functions?

SENSICARDIAC's AI algorithm for murmur detection has reported accuracy above 95%, with a sensitivity of 91% and a specificity of 94% in studies involving children. VX1 assists in the real-time identification of dispersed electrograms during ablation procedures and includes a 'Booster mode' for increased sensitivity during atrial tachycardia or slow atrial fibrillation.

Given their specialized applications, what is the expected learning curve for a physician to become proficient with each tool, and what training resources are provided?

SENSICARDIAC features a guided auscultation process, suggesting a potentially lower learning curve for general practitioners. VX1, integrated with complex EP lab systems for real-time procedural guidance, would likely involve a more specialized and potentially steeper learning curve for electrophysiologists, though specific training resources are not detailed.

Beyond standard compliance, what specific audit-trail capabilities and advanced security measures does each tool offer to ensure data integrity and accountability?

SENSICARDIAC provides downloadable PDF reports, which inherently offer a record of findings, but no explicit advanced audit-trail features are mentioned beyond standard cloud security. VX1's integration with EP lab systems implies it would leverage the audit capabilities of those systems, though specific features like immutable logging or real-time monitoring are not detailed.

What are the key considerations for deploying each tool across multiple clinical sites, and what is the typical time-to-value for realizing their benefits?

SENSICARDIAC, being cloud-based with electronic stethoscope integration, could facilitate multi-site rollout for screening, potentially offering a quicker time-to-value by reducing unnecessary referrals. VX1's integration with existing EP lab systems means multi-site deployment would depend on compatibility with each lab's specific setup, with time-to-value likely realized immediately through enhanced procedural guidance.

Are customer references or case studies available to demonstrate real-world efficacy, and what level of ongoing technical and clinical support can be expected?

The provided information does not explicitly state the availability of customer references, case studies, or the specific level of ongoing technical and clinical support for either SENSICARDIAC or VX1. Physicians would need to inquire directly with the respective companies for this information.